X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KRAZATI (adagrasib) is a highly selective and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, being evaluated in Phase III clinical trial studies for the treatment of locally advanced or metastatic non-small cell lung cancer.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
ZL-1310 is an innovative Antibody-Drug-Conjugate targeting DLL3, it is being developed as a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors.
Lead Product(s): ZL-1310
Therapeutic Area: Oncology Product Name: ZL-1310
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
TPX-0005 (repotrectinib) is a next-generation tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of advanced solid tumors, including NSCLC.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
TPX-0005/BMS-986472 (repotrectinib) is a oral next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting ROS1- or NTRK-positive locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC).
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
TPX-0005 (repotrectinib) is small macrocyclic tyrosine kinase inhibitor of ROS1, TRK and ALK. Repotrectinib was designed to efficiently bind with the active kinase conformation and avoid steric interference from a variety of clinically resistant mutations.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Turning Point Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Paratek Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
In TKI-naive patients for repotrectinib, in 71 total patients, there was a cORR of 79% across global trial. Ten of 11 patients responded within China for a cORR of 91% and DOR ranged from 3.6+ to 7.5+ months with a median duration of follow-up of 3.7 months.
Lead Product(s): Repotrectinib
Therapeutic Area: Oncology Product Name: TPX-0005
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Turning Point Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
PRIME study demonstrates that Zejula (niraparib) treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the overall study population regardless of biomarker status when compared to placebo.
Lead Product(s): Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Zejula
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Under the terms of the agreement, Zai Lab will fund for the development, manufacturing, and commercialization of KarXT (xanomelinetrospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Karuna Therapeutics
Deal Size: $187.0 million Upfront Cash: $35.0 million
Deal Type: Collaboration November 09, 2021
Details:
Under the terms of the agreement, Zai Lab will be responsible for all the development costs for BLU-945 and BLU-701 occurring in Greater China and will receive the rights to develop and exclusively commercialize BLU-945 and BLU-701 in the region.
Lead Product(s): BLU-945
Therapeutic Area: Oncology Product Name: BLU-945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Blueprint Medicines
Deal Size: $615.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration November 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
